BioCentury
ARTICLE | Clinical News

Faldaprevir: Interim Phase IIa data

October 3, 2016 7:00 AM UTC

Interim data from 11 treatment-naive, non-cirrhotic patients with chronic HCV genotype 4 infection in an open-label, U.S. Phase IIa trial showed that once-daily 60 and 120 mg TD-6450 plus once-daily ...